Muscle or bone? The answer changes the treatment
Some patients find a square jawline too strong — reading masculine, heavy, or out of proportion with the upper face. Most of the time, what feels like a wide jaw is not bone at all. It is the masseter, the chewing muscle at the angle of the jaw, that has enlarged from clenching, grinding, or chronic tension. That distinction shapes every consultation: muscle responds to neuromodulator injection reliably and non-surgically, while bony width is a different conversation that may end with an honest referral.
Dr. Natalya Borakowski, NMD begins every square-jaw consultation with palpation under clench. The muscle balls up on bite, bone does not — that simple test usually tells us which path applies. Related concerns: jowling, weak chin, facial asymmetry.
The Driver: Hypertrophic Masseter Muscle, Not Bone Structure

The masseter is the primary chewing muscle, sitting at the angle of the jaw. Like any muscle, it enlarges with overuse — chronic clenching, bruxism, heavy gum chewing, and stress-driven jaw tension all build masseter volume over months and years. In women presenting with a square jaw, muscle hypertrophy is the dominant driver in the vast majority of cases. That is what makes the concern highly treatable without surgery: shrink the muscle, narrow the lower face.
Bone contributes for some patients. A naturally wider mandible creates a square shape regardless of muscle size, and many presentations combine both factors. The diagnostic test is direct: palpate the masseter while the patient clenches. A hypertrophic muscle visibly balls up; bony width is constant whether the jaw is relaxed or contracted. One anatomical note — enlarged salivary glands and submental fat can mimic the look. Dr. Borakowski rules those out before recommending any jaw-slimming treatment.
Treatments at Desert Bloom
Five treatments cover the spectrum of square-jaw cases — from muscle-only Botox sessions to multi-modality balancing when the lower face needs coordinated work. Which path applies depends on whether the driver is muscle, bone, combined, or part of a broader feminization goal.

First-line for muscle bulk
Botox — Masseter Reduction
Standard-of-care first step for muscle-driven squareness. 25–50 units per side (typically 25–30, titrated higher for larger muscles), gradual atrophy over 4–6 weeks, peak narrowing at 6–8 weeks, results last 4–6 months. Bruxism co-benefit: jaw tension and morning soreness ease as the muscle relaxes.

Neuromodulator alternative
Dysport — Masseter
Botulinum toxin type A with slightly faster onset and broader diffusion within the muscle. Same clinical mechanism and outcome target as Botox; Dysport dosing scales roughly 3:1 (not interchangeable unit-for-unit). For patients with prior Dysport preference or choosing it for first masseter treatment.

Longer interval option
Daxxify — Masseter
Botulinum toxin formulated for longer duration — roughly 2:1 vs Botox in units, with maintenance intervals that may extend beyond 4–6 months. Same mechanism, different molecular profile. Useful when patients want fewer visits per year, though Dr. Borakowski's view is that longer-lasting requires more certainty the treatment is right.

Feminization context
Non-Surgical Facial Feminization
When square-jaw concern is part of a broader feminization goal — softer mandibular angle, fuller cheeks, refined chin — a coordinated session addresses multiple structural drivers in one plan. Combines masseter neuromodulator with filler placements that round the lower face and re-balance the V-line.

Multi-modality balancing
Aesthetic Facial Balancing
When jaw width is one of several lower-face imbalances — weak chin, flat cheeks, asymmetry — a coordinated facial-balancing session maps and treats all contributing factors. Not every jaw case needs this; many need only masseter Botox. Reserved for cases where context, not just muscle, drives the read.
Find your path
Which Square Jaw Are You?
The driver determines first-line treatment. Dr. Borakowski reads this on palpation at the consultation — the right route is usually obvious within minutes.
Masseter-dominant — muscle balls up when I clench
→Botox Treatment — Botox masseter 25–50 units per side (or Dysport / Daxxify equivalent). First-line, reliably non-surgical.
Combined with bruxism — grinding, jaw soreness, headaches
→Botox Treatment — Same masseter neuromodulator path. Cosmetic + functional co-benefit. Dental co-management for occlusion stays separate.
Part of a broader feminization goal — not just jaw
→Non-Surgical Facial Feminization — Non-Surgical Facial Feminization coordinates masseter neuromodulator with filler for chin, cheeks, and overall V-line refinement.
Width plus chin or cheek imbalance — context matters
→Aesthetic Facial Balancing — Aesthetic Facial Balancing maps the full lower face and treats jaw, chin, and cheek together in one coordinated plan.
Surgical referralBone-dominant — width is constant whether I clench or relax
→Honest assessment first — Limited response to neuromodulators. Surgical mandibular reduction is outside non-surgical scope — we refer to oral/maxillofacial surgery honestly.
Frequently Asked Questions
Does masseter Botox actually slim the face?
How many units of Botox are needed for the jaw?
What about Dysport or Daxxify for masseter treatment?
How long do masseter results last?
What if my squareness comes from bone, not muscle?
Can men get masseter Botox for a square jaw?
Will people notice my jaw is different after treatment?
“Most square-jaw consultations end the same way — a few cycles of masseter Botox, a year of follow-up, and we revisit whether definition or lift is still missing. Almost always, narrowing the muscle is enough on its own. The cases where I refer out — true bony angle without significant masseter — I would rather tell you early than let you spend money on something that won't move the needle.”

Medically reviewed by
Founder, Desert Bloom Skincare · 17 Years Experience
References
- 1.
Seok J, Koh YG, Hong JK, Yun SH, Kim DH, Son HS. Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study. Dermatol Surg; 2024.
DOI: 10.1097/DSS.0000000000004146
Phase-3 RCT supports jaw-narrowing onset, peak, and 4–6 month duration claims for botulinum toxin A in masseter hypertrophy.
- 2.
Yeh YT, Peng JH, Peng HP. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy. J Cosmet Dermatol; 2018.
DOI: 10.1111/jocd.12721
Safety profile and dosing-range context for masseter Botox; anchors 25–50 U per side titrated-by-muscle-size language.
- 3.
Yan M, Zhao M, Liu J, Luo Y, Qiu Y, Guo Z, Yu P, Lu J. What Happened to Masticatory Muscles after Botulinum-Toxin-Type A Injection into Masseter: A Systematic Review. Aesthetic Plast Surg; 2026.
DOI: 10.1007/s00266-025-05410-w
Systematic review of masticatory muscle outcomes after botulinum toxin A injection into masseter; supports efficacy and safety framing.
